ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

This study has been completed.

Sponsored by: United Biomedical
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier: NCT00002353
  Purpose

To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered subcutaneously in HIV-seropositive patients.


Condition Intervention Phase
HIV Infections
Biological: P3C541b Lipopeptide
Phase I

MedlinePlus related topics:   AIDS   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Placebo Control, Safety Study
Official Title:   A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Detailed Description:

Patients are randomized to receive P3C541b or placebo within each of two study groups. Enrollment in the first group will be independent of HLA type, whereas all but two of the patients enrolled in group 2 must have one or more HLA types A33, B8, B27, or Bw62. Treatment in group 2 will not begin until those in group 1 have reached day 14 without serious toxicity.

  Eligibility
Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

Patients must have:

  • HIV positivity.
  • CD4 count >= 500 cells/mm3.
  • No evidence of AIDS, persistent diarrhea, fever, oral hairy leukoplakia, herpes varicella-zoster (multidermatomal), oral candidiasis, opportunistic infections, severe cytomegalovirus infection, or disseminated or chronic herpes simplex.
  • Successful establishment of EBV transformed B lymphoblastoid cell line.

NOTE:

  • Most patients in group 2 must possess one or more HLA types A33, B8, B27, or Bw62.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Active syphilis.
  • Positive circulating hepatitis B virus antigen.
  • Active clinically significant medical problems.
  • Evidence of psychiatric, medical, or substance abuse problems that would affect ability to participate on study.
  • Occupational or other responsibilities that would prevent completion of study.

Concurrent Medication:

Excluded:

  • Other HIV immunotherapeutic.
  • Zidovudine or analog.
  • Investigational therapies for HIV.

Patients with the following prior conditions are excluded:

  • History of cancer unless surgically excised with reasonable assurance of cure.
  • History of anaphylaxis or other serious adverse reactions to vaccines.
  • History of serious allergic reaction to any substance that required hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasms, or hypotension).
  • History of autoimmune disease or use of immunosuppressive medications.
  • History of suicide attempts or past psychosis.

Prior Medication:

Excluded within the past 6 months:

  • HIV immunotherapeutic.
  • Zidovudine or analog.
  • Investigational therapies for HIV. Illicit drug use within past 30 days.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002353

Locations
United States, Massachusetts
Beth Israel Hosp    
      Boston, Massachusetts, United States, 02215

Sponsors and Collaborators
United Biomedical
  More Information


Study ID Numbers:   090, V103B
First Received:   November 2, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00002353
Health Authority:   United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Vaccines, Synthetic  
AIDS Vaccines  

Study placed in the following topic categories:
Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Lentivirus Infections
Infection

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers